Literature DB >> 2473282

Positive inotropic and vasoconstrictive effects of endothelin-1 in in vivo and in vitro experiments: characteristics and the role of L-type calcium channels.

T Watanabe1, K Kusumoto, T Kitayoshi, N Shimamoto.   

Abstract

Cardiac and vascular effects of endothelin-1 (ET-1) were studied in hemodynamic models in vivo and in isolated artery and heart tissues. The hemodynamic changes induced by ET-1 (30-300 pmol/kg i.v.) in dogs were increases in blood pressure, cardiac output, and ventricular contractility. Ring preparations of canine coronary artery and rabbit thoracic aorta showed vasoconstrictive responses to ET-1 (10(-10) M and over) with an EC50 of 3-10 x 10(-9) M. Nifedipine 10(-5) M did not reverse these effects completely. ET-1 had positive inotropic effects from 10(-10) M in rabbit papillary muscles. It lengthened the action potential duration by 16% and increased the developed tension by 180% (10(-8) M). In contrast, Bay K 8644 (10(-7) M) produced similar lengthening (17%) in the duration with only a 37% increase in the tension. This suggests a difference in the mechanisms of the positive inotropic effects between these two agents. We conclude that ET-1 has positive inotropic and vasoconstrictive effects, and that these ET-1-induced contractions in ventricular muscles and arteries cannot be explained thoroughly by the increase in currents through voltage-dependent calcium channels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473282     DOI: 10.1097/00005344-198900135-00027

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway.

Authors:  R A Kelly; H Eid; B K Krämer; M O'Neill; B T Liang; M Reers; T W Smith
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

2.  Endothelin activates voltage-dependent Ca2+ current by a G protein-dependent mechanism in rabbit cardiac myocytes.

Authors:  M R Lauer; M D Gunn; W T Clusin
Journal:  J Physiol       Date:  1992-03       Impact factor: 5.182

3.  Pharmacological characteristics of endothelin receptors in the rabbit ventricular myocardium: the nonselective endothelin receptor antagonist PD 145065 antagonizes the positive inotropic effect of endothelin-3 but not of endothelin-1.

Authors:  I Norota; M Endoh
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

4.  Endothelin-1-induced constriction in the coronary resistance vessels and abdominal aorta of the guinea pig.

Authors:  A Folta; I G Joshua; R C Webb
Journal:  Heart Vessels       Date:  1990       Impact factor: 2.037

Review 5.  Role of endothelin in hypertension.

Authors:  B K Krämer; M Ackermann; S M Kohler; G A Riegger
Journal:  Clin Investig       Date:  1994-01

6.  The effect of diltiazem on the coronary haemodynamic and cardiac functional effects produced by intracoronary administration of endothelin-1 in the anaesthetized dog.

Authors:  A J Nichols; P F Koster; E H Ohlstein
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

7.  Effects of endothelin-1 on epicardial coronary tone, coronary blood flow, ECG-ST change and regional wall motion in anesthetized dogs.

Authors:  K Muramatsu; H Tomoike; Y Ohara; S Egashira; M Nakamura
Journal:  Heart Vessels       Date:  1991       Impact factor: 2.037

Review 8.  Endothelin and myocardial ischemia.

Authors:  D Hasdai; R Kornowski; A Battler
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

9.  Endothelin-1 inhibits L-type Ca currents enhanced by isoproterenol in guinea-pig ventricular myocytes.

Authors:  L H Xie; M Horie; A F James; M Watanuki; S Sasayama
Journal:  Pflugers Arch       Date:  1996-02       Impact factor: 3.657

10.  Hemodynamic and inotropic effects of endothelin-1 in vivo.

Authors:  M E Beyer; S Nerz; B K Krämer; H M Hoffmeister
Journal:  Basic Res Cardiol       Date:  1994 Jan-Feb       Impact factor: 17.165

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.